Why the study?
Overactivation of the classical RAS and depletion of the non-classical RAS leads to vascular dysfunction and disease, prompting interest in ACE2 activators like diminazene aceturate (DIZE).
Design
Review
Authors
Loading...
May guide RAS modulator development in hypertension; leaves open clinical translation without prospective trials.
This review highlights the potential of the ACE2 activator diminazene aceturate (DIZE) as a therapeutic agent in cardiovascular and other diseases by counterbalancing the classical renin-angiotensin system.
Qaradakhi et al. (2020) studied this question.